Dash Acquisitions Inc. Reduces Stake in Thermo Fisher Scientific Inc. $TMO

Dash Acquisitions Inc. cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 12.6% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,547 shares of the medical research company’s stock after selling 4,249 shares during the period. Thermo Fisher Scientific comprises about 2.9% of Dash Acquisitions Inc.’s holdings, making the stock its 12th largest position. Dash Acquisitions Inc.’s holdings in Thermo Fisher Scientific were worth $14,331,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in TMO. Deseret Mutual Benefit Administrators raised its holdings in shares of Thermo Fisher Scientific by 24.8% in the third quarter. Deseret Mutual Benefit Administrators now owns 392 shares of the medical research company’s stock worth $190,000 after acquiring an additional 78 shares during the last quarter. UniSuper Management Pty Ltd raised its stake in Thermo Fisher Scientific by 7.0% in the 3rd quarter. UniSuper Management Pty Ltd now owns 137,940 shares of the medical research company’s stock valued at $66,904,000 after purchasing an additional 8,982 shares during the last quarter. Jennison Associates LLC lifted its holdings in Thermo Fisher Scientific by 51.5% in the 3rd quarter. Jennison Associates LLC now owns 251,467 shares of the medical research company’s stock valued at $121,967,000 after purchasing an additional 85,475 shares in the last quarter. Hunter Associates Investment Management LLC boosted its stake in shares of Thermo Fisher Scientific by 0.8% during the 3rd quarter. Hunter Associates Investment Management LLC now owns 11,284 shares of the medical research company’s stock worth $5,473,000 after purchasing an additional 84 shares during the last quarter. Finally, Westfuller Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 160.7% during the third quarter. Westfuller Advisors LLC now owns 1,348 shares of the medical research company’s stock worth $654,000 after buying an additional 831 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Barclays lifted their price objective on Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Friday, January 9th. Leerink Partners boosted their target price on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Hsbc Global Res raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday, December 1st. Finally, TD Cowen reissued a “buy” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $625.47.

Insider Activity

In other Thermo Fisher Scientific news, EVP Frederick M. Lowery sold 6,913 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the completion of the sale, the executive vice president owned 14,367 shares in the company, valued at $8,586,868.56. The trade was a 32.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Lisa P. Britt sold 10,225 shares of the business’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the sale, the vice president directly owned 14,145 shares of the company’s stock, valued at approximately $8,085,564.90. This represents a 41.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 131,767 shares of company stock valued at $76,467,793 over the last three months. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $625.42 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company’s fifty day moving average price is $590.88 and its two-hundred day moving average price is $530.87. The firm has a market capitalization of $234.98 billion, a P/E ratio of 36.13, a P/E/G ratio of 4.21 and a beta of 0.91. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same period in the prior year, the business posted $5.28 EPS. The business’s revenue was up 4.9% on a year-over-year basis. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date was Monday, December 15th. Thermo Fisher Scientific’s payout ratio is 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock buyback plan on Thursday, November 6th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.